Member Info for ThinIce

We know their cash burn is £500k a month, but do we know what proportion of this is salaries?

Thanks Kev4 Whilst it is good that funding options are being considered this early into the cycle, I hope it doesn't hang over us in 2017. TI

Thanks Cookie Someone was suggesting either here or on ADVFN that a competitor in Episalvan's marketplace was bought out at the start of their Phase 3 trial. Is this usual and could you see the same happening here? In light of your last comment regarding the size of the potential market, it is surprising that the AP102 news failed to have any effect on the share price. Have a great weekend TI

Hi all Do we think the AP102 Orphan Drug Designation is the last news for 2016? I suspect the EMA ODD will be in the new year along with news of the start of the Episalvan Phase 3 trials. Is there the potential for a partnership deal with any of the above or Imlan any time soon? Just interested in any views....to offset the tedium! Thanks in advance TI

Hi equitrder Point taken. However, I personally would be more concerned if Wiley, Nealon (and to some extent) Friel didn't hold any stock. I suspect for each of the above, the success or failure of this venture will be life changing. OK, it would be a good signal to the market if Stratford were to buy in too, but this would be a token gesture for a man who has more money than he needs.

Thanks Kev4. Still a way to go on this one. Bring on the EB P3.

Morning Early Bird What does: 'prepare to bring AP102 into the clinic next year'. Does this merely mean start trials? Thanks in advance!

Yes - he was there before Amryt. Judging by Innocoll's share price crash, they're probably hoping he rings them!

What is the relevance to Amryt please?

I have always found it odd that a few thousand pounds worth of trades can knock millions off a company's valuation! The recent movements have been entirely disproportional to the trading activity.

How is commenting on some trades 'pumping'?

They are giving a presentation at the offices Shard Capital next Tuesday (I don't have a link, but mentioned on ADVFN). That will be an opportunity to update investors and I wouldn't be surprised if it's timed to coincide with news. Shard began coverage of Amryt in April 2016.

Thanks ShrewDEds. Forgive my subdued response to your earlier post! Getting a bit impatient with this lot now. I've been holding for 3+ years largely on promises of better times ahead but only to try and recover my £27k overall investment (in oil and gas mainly). To say I've heard it all before is an understatement! GOOD NEWS is all that will do it I feel. Here's hoping for some (and that Friel can deliver on at least one promise in my (and his) lifetime). All the very best. TI

Thanks. Found 'her' now (Nicola not Nicolas). Still not sure it's a qualified support level.

Wondering why anyone thinks this is a support level. It dropped Friday and its not been tested yet with any selling volume! Can I ask who this Nicolas Duke is please?

The Dublin office is in fact the office of Raglan Capital which is owned by Cathal Friel. I suspect the business is registered there but I doubt this is where any staff are based.

Hi Propinquity - I don't disagree. I think its a fabulous line up and I am optimistic that we have very exciting times ahead. Like many, I am here due to my investment in Fastnet and so its a bit of a learning curve for me. The only legacy that remains from Fastnet is Friel and I sat through a few presentations where he made comments which were not founded on fact. I just hope that his fellow directors are able to reign him in. I wish everyone here the very best of luck.

There's a video from 2014 where Cathal (as Chairman of Fastnet) says: 'if we are still here in 3 years time, we are not doing our job properly'. I was there and I wouldn't believe a word he says. As it happens, Fastnet isn't still here so he can argue he was right. That said, the other board members are far more discerning and hopefully they will reign the bumbling fool in! Just a view!

So who has dumped? Hardly any volume.

There was no negative news when the share price fell 30%, so why does there have to be positive news when it rises 16%? Maybe the book just looks better?